SOUTH SAN FRANCISCO, Calif., Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ...
Rigel Pharmaceuticals has seen its fair value estimate nudged up from US$49.60 to US$51.20, with only a small adjustment to the discount rate from 7.12% to 7.14% and revenue growth assumptions kept at ...
Don't miss 'The Curse of Rigel ' Expansion Launch Trailer for Wartales, an open-world turn-based strategy RPG developed by Shiro Games. Players will enforce the King's will to venture into the County ...
It seems like it’s going to be one award after another this season for Paul Thomas Anderson. Warner Bros’ action epic “One Battle After Another” was named the best film of the year by the New York ...
Paul Thomas Anderson’s “One Battle After Another” was named the best film of 2025 by the New York Film Critics Circle, which announced its annual awards on Tuesday. While the film went into the ...
Rigel Pharma is a profitable biotech with three FDA-approved drugs, experiencing accelerating revenue growth led by Tavalisse's strong performance. RIGL trades at a significant discount to biotech ...
Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 ...
SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported net income of $27.9 million in its third quarter. On a per-share basis, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback